TSE:4151Pharmaceuticals
How Investors Are Reacting To Kyowa Kirin (TSE:4151) Real-World Data On Mogamulizumab’s Patient Benefits
Kyowa Kirin recently reported positive results from its PROSPER real-world observational study, showing that mogamulizumab improved skin symptoms in adults with mycosis fungoides or Sézary syndrome as early as week 4, with benefits maintained through week 48.
The findings highlight that beyond clinical measures, mogamulizumab may meaningfully ease daily-life burdens for patients by improving sleep and overall health-related quality of life over nearly a year of treatment.
With new real-world...